Guidance, NICE advice and quality standards in development | Guidance

Showing 61 to 70 of 394

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]	Technology appraisal guidance	24 May 2019
Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment [ID6474]	Technology appraisal guidance	19 November 2025
Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma [ID6330]	Technology appraisal guidance	TBC
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]	Technology appraisal guidance	TBC
Capivasertib with abiraterone for treating hormone-sensitive metastatic prostate cancer with PTEN deficiency [ID6466]	Technology appraisal guidance	TBC
Capsule sponge tests for surveillance of Barrett's oesophagus (provisional title)	Health technology evaluation	TBC
Cardiometabolic disease prevention and treatment guidelines	NICE guideline	TBC
Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable ID6580	Technology appraisal guidance	30 September 2026
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]	Technology appraisal guidance	TBC
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]	Technology appraisal guidance	TBC